CC BY-NC-ND 4.0 · Laryngorhinootologie 2021; 100(S 02): S281
DOI: 10.1055/s-0041-1728634
Abstracts
Rhinology: Nasal cavity / Paranasal Sinuses

Monoclonal antibodies for the therapy of severe chronic rhinusinusitis with nasal polyps (CRSwNP) - first experiences in clinical routine

P Nahrath
1   HNO Uniklinik Dresden, Dresden
,
M Cuevas
2   HNO- Uniklinik Dresden, Abt. für Allergologie/ Rhinologie, Dresden
,
T Zahnert
3   HNO- Uniklinik Dresden, Dresden
› Author Affiliations
› Further Information
Also available at
 
 

    Introduction Chronic rhinosinusitis (CRS) is an inflammation of the nose and paranasal sinuses, which leads to a severe reduction in quality of life. If the disease cannot be controlled despite conservative and surgical measures, biologicals can open up new perspectives in treatment. Clinical studies have shown a significant reduction in polyp size, an improvement in olfactory function and quality of life. Recently, Dupilumab and Omalizumab were approved as add-on therapy to topical corticoids in Germany for severe CRSwNP. We report the first results in clinical routine.

    Methods Since January 2020, 28 patients with severe and under standard therapy uncontrolled CRSwNP have been treated with Dupilumab. The data were evaluated with regard to polyp score, olfactory function and quality of life (SNOT-20). To date, these patients have been treated for at least 16 weeks (n=20).

    Results During the whole observation period the polyp score decreased significantly (day 0: m=6.0; after 16 weeks: m=2.0; p  <  0.01). The olfactory ability improved significantly (day 0: m=2.6; after 16 weeks: m=7.2; p  <  0.01). At the same time, the determined quality of life improved (SNOT-20: day 0: m=46.9, week 16: m=19.2; p  <  0.01).

    Overall, there was good tolerability, but 3 patients reported newly occurring musculoskeletal pain.

    Conclusion With the present study we show the positive experience of the efficacy of biologicals in patients with severe uncontrolled CRSwNP despite standard therapy. The therapy with Dupilumab reduced the size of the polyps, improved the olfactory perception and the quality of life of the patients with overall good tolerability. The observed musculoskeletal complaints were not described before and have been included in the medical product information.

    Poster-PDF A-1159.pdf


    #

    Conflict of interest

    Der Erstautor gibt keinen Interessenskonflikt an.

    Address for correspondence

    Dr. med. Nahrath Philipp
    HNO Uniklinik Dresden
    Dresden

    Publication History

    Article published online:
    13 May 2021

    © 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

    Georg Thieme Verlag KG
    Rüdigerstraße 14, 70469 Stuttgart, Germany